

**Remarks**

The specification has been amended to include a "Statement as to Federally Sponsored Research." The amendment indicates the name of the granting agency and grant number and, therefore, addresses an informality. As such, the amendment to the specification does not add new matter and entry thereof is respectfully requested.

**Conclusion**


If the fee authorized is incorrect or if any other fees are due in connection with this submission, please charge any such fee or credit any overpayment to Deposit Account No. 03-3975.

Respectfully submitted,

PILLSBURY WINTHROP LLP

Date: 2-19-02

By: \_\_\_\_\_

  
Robert M. Bedgood  
Reg. No. 43,488

50 Fremont Street  
P.O. Box 7880  
San Francisco, CA 94105  
Tel. No.: (858) 509-4065  
Fax No.: (415) 983-1200



## MONOCYTE CHEMOATTRACTANT ACTIVITY OF GALECTIN-3

5

### **Field of the Invention**

#### **Statement as to Federally Sponsored Research**

This work was supported in part by National Institute of Health Grant No. RO1 AI39620. The government may have certain rights in the invention.

10

#### **Cross Reference to Related Applications**

This application is based on Provisional Application Ser. No. 60/188,795, which was filed on Mar. 13, 2000, and priority is claimed thereto.

#### **Field of the Invention**

15

The present invention relates to methods for modulating migration of cells, especially monocytes, neutrophils and macrophages, using galectin-3, galectin-3 binding polypeptides, galectin-3 receptor binding polypeptides or galectin-3 mimetics. The invention also relates to screening methods for identifying agents that modulate galectin-3-mediated cell migration.

20

#### **Background of the Invention**

Lectins are proteins that bind to specific carbohydrate structures and can thus recognize particular glycoconjugates. Galectins are a family of over 10 structurally related lectins that bind beta-galactosides.

25

Galectin-3 is a 26 kDa beta-galactoside-binding protein belonging to the galectin family. This protein is composed of a carboxyl-terminal carbohydrate-recognition domain (CRD) and amino-terminal tandem repeats. Galectin-3 is found in epithelia of many organs, as well as in various inflammatory cells, including macrophages, dendritic cells and Kupffer cells. The expression of galectin-3 is upregulated during inflammation, cell proliferation, cell differentiation, and through transactivation by viral proteins. Its expression is also affected by neoplastic transformation -- upregulated in certain types of lymphomas and thyroid carcinoma; downregulated in other types of malignancies, such as colon, breast, ovarian and uterine carcinomas. Recently, it has been reported that the expression of this lectin has a strong correlation with the grade and malignant potential of primary brain tumors. Increased galectin-3 expression has also been noted in human atherosclerotic lesions. These findings suggest that galectin-3 may mediate both physiological and pathological responses.

30

35